Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Invikafusp alfa + Sacituzumab Govitecan in advanced solid tumors
NCT06827613Phase 2Recruiting
- Sponsor
- Marengo Therapeutics
- Start
- Mar 2025
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics, Bispecific Antibodies, Fc-Fusion Proteins
- Countries
- 2
01
Overview
Phase 2, open-label trial of invikafusp alfa in breast cancer (2 arms), sponsored by Marengo Therapeutics. Primary endpoints: Dose Limiting Toxicities at 21 days, Adverse Events at 3 years and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
invikafusp alfa
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06827613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06827613.